Tilray Stock Buy or Sell? TLRY Stocks Forecast

Market Capitalization: 1 328 995 000 $
EBITDA: -45 457 000 $
Price to Earnings: None
Quarterly Earnings Growth YOY: N/A
Quarterly Revenue Growth YOY: 0.344
Trailing PE: -
Forward PE: 1000
Shares Outstanding: 755111000






Trading Penny Stocks for Profit: Expert Insights and Practical Advice

February 22, 2024 Trading Penny Stocks for Profit: Expert Insights and Practical Advice

For aspiring traders and seasoned investors alike, the enticing appeal of penny stocks can be likened to voyaging across the vast oceans, discovering…
Getting A Kredittkort Norge Approval Isn’t Difficult

February 8, 2024 Getting A Kredittkort Norge Approval Isn’t Difficult

If you meet the conditions, you can open an account for checking in Norway. However, it will be much easier and more convenient…
How to Understand Social Security: 6 Legal & Financial Tips

January 25, 2024 How to Understand Social Security: 6 Legal & Financial Tips

Understanding social security can seem overwhelming, but it’s an important part of financial planning, particularly for retirement. The following 6 legal and financial…
Finding Energy Plans with Billig Strøm Rates

January 10, 2024 Finding Energy Plans with Billig Strøm Rates

It can be overwhelming to decide on the best plan when in a state where electricity is deregulated. The number of providers is…

Tilray Stock Buy or Sell? TLRY Stocks Analytic Forecasts

Updated on February 27, 2024 (10:18)

Tilray, Inc. (TLRY prediction charts) Sector: Healthcare

We present you the most up-to-date and complete review of analytical trend forecasts and views on the TLRY stock market. Experts share their opinions on what to expect from the Tilray, Inc. stock market. How likely is the stock price to move in a bullish or bearish trend. Which should help you to make the right decision whether to Buy or Sell Tilray stocks.

Tilray, Inc. Stock Market Experts’ Analysis and Forecasting – Sell or Buy TLRY Shares?

The most recent analytical view which can help you to answer the worrying question: Should I Buy Stocks Now or Wait? came out under the authorship of Stone Fox Capital and is titled

“Tilray: Beverages Headache”

is published on January 10 (2024) and has 0 likes. The review predicts Neutral market trend.

It summarize the following theses:

  • Tilray Brands, Inc.’s growth is driven by acquisitions, not organic growth in the cannabis business.
  • The company’s focus has shifted towards beverages, with recent acquisitions from Anheuser-Busch.
  • Tilray Brands stock offers limited value, with Tilray needing to hit aggressive adjusted EBITDA targets before investors will gain any confidence the business can be managed.

The author starts his analytic review with the following:

Tilray Brands, Inc. (NASDAQ:TLRY) reported another quarter where growth was all about acquisitions and not actually growing the cannabis business. The company has long struggled to report any consistent growth and the business is now virtually a non-cannabis operation with the new focus on beverages. My investment thesis remains Neutral on the stock following the fiscal FQ2 results, with Tilray shares dipping back below $2.

This author is very popular among the auditory. He has 45605 followers

Stone Fox Capital is the contributor of experts community since 2008 and has a great number of published articles – 4921.


One more noteworthy article is written by Bill Maurer under the title

“Tilray Remains Stuck In Neutral”

on January 10 (2024) and has 1 likes. The expert reflects Neutral trend of the market.

Нis theses make you think about whether to add TLRY stocks to your investment portfolio or not, and helps to work out your own Tilray stock selling strategies:

  • Tilray reported Q2 revenue of $194 million, up 34% YoY but slightly below analyst estimates.
  • The company continues to lose money and burn cash, with a large amount of debt sitting on its balance sheet.
  • Should we get a major equity raise or federal US legalization of cannabis, the stock could be worth a look.

Bill Maurer starts analysis with such words:

On Tuesday morning, we received fiscal second quarter results from Canadian cannabis and beverage firm Tilray (NASDAQ:TLRY). The company was one of the biggest examples of the cannabis boom and bust a number back in 2018, seeing shares surge to $300 before crashing back to nearly zero. While the company is making progress to become a more complete business, it hasn’t made enough strides just yet to get my full blessing.

This author is very popular among the auditory. He has 34938 followers

Bill Maurer is the contributor of experts community since 2011. Has published at least 3199 articles.


Another analysis presented by Daniel Jones came out on January 9 (2024). Obviously, coupled with the newer reviews, this forecasting could be useful to find out the best trading strategy for TLRY stocks. It sounds like

“Tilray Brands Fiscal Q2 Earnings: Downside Is Far From Over”

Article has got 1 likes at the moment and forecasting Bearish trend of the market.

Summarizing the information presented in the review concerning the Tilray, Inc., the expert says the following:

  • Tilray Brands, Inc. shares dropped 9.4% after falling short of revenue and GAAP earnings forecasts in its fiscal Q2 2024 financial results.
  • The company reported robust growth in its beverage alcohol operations, but overall growth and improvement are not enough to make it a viable prospect for investors.
  • Despite growth, Tilray Brands has issues and looks very expensive at this point in time.

And here, what comes first:

January 9th was not that pleasant a day for shareholders of cannabis firm Tilray Brands, Inc. (NASDAQ:TLRY). Shares of the company dropped around 9.4% after management reported financial results covering the second quarter of the company’s 2024 fiscal year. Although the business exceeded expectations when it came to adjusted earnings per share, it fell short of forecasts when it came to both revenue and GAAP earnings.

This author is very popular among the auditory. He has 29776 followers.

Daniel Jones is the contributor of experts community since 2014 and has at least 4256 analytic reviews published.


The Share Price of Tilray, Inc. (TLRY) for now

What analysts predict: $2.47
52-week high/low: $3.4 / $1.5

50/200 Day Moving Average: $2.001 / $2.072

The average stock price over the previous 50/200 days. For Tilray stocks, the 50-day moving average is the resistance level for now. For TLRY stocks, the 200-day moving average is the resistance level today.

See the Detailed Predictions for TLRY stock with charts and tables

Related Analysis

View all analytics

Buy or Sell ADGI shares?
January 1, 1970

Thermo Fisher’s Bright Future Makes It A Great Buy On Weakness

Buy or Sell TMO shares? Thermo Fisher’s Bright Future Makes It A Great Buy On Weakness
February 6, 2024
Drug manufacturers are facing a massive patent cliff, with over $200 billion in annual revenue at risk through 2030, meaning innovation is critical to prop up sales, and today's company focuses on that.

Revisiting Zynerba Pharmaceuticals

Buy or Sell ZYNE shares? Revisiting Zynerba Pharmaceuticals
November 11, 2021
Today, we revisit a small developmental firm called Zynerba Pharmaceuticals.

Danaher: Better Positioned For The Future

Buy or Sell DHR shares? Danaher: Better Positioned For The Future
February 3, 2024
Danaher's annual results show a decrease in sales and EBIT due to the boost in sales of the COVID-19 pandemic.